Genmab — November 2016
-
Vi er tæt på 10%.
-
Tænk sig at have så mange forsøg i gang at J&J ikke kan have alle med på ASH, men er i en position hvor de kan vælge de mere modne data og vente med de mere umodne, troede ikke deres kapacitet skulle udfodres men det bliver den åbenbart af Darzalex selvom over 800 arbejder på midlet.
-
378.000 aktier omsat
-
It´s more than ok.
-
A guidance hike was on the cards but Genmab delivered more than expected. Twenty daratumumab abstracts (six oral presentations) were accepted for ASH. We lift our 12-month target price to DKK1,470 and keep our Buy recommendation in the wake of the Q3 16 results.
-
(Y) Stærkt arbejde Helge
)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind